Author: Huijie Bian; Zhao-Hui Zheng; Ding Wei; Zheng Zhang; Wen-Zhen Kang; Chun-Qiu Hao; Ke Dong; Wen Kang; Jie-Lai Xia; Jin-Lin Miao; Rong-Hua Xie; Bin Wang; Xiu-Xuan Sun; Xiang-Min Yang; Peng Lin; Jie-Jie Geng; Ke Wang; Hong-Yong Cui; Kui Zhang; Xiao-Chun Chen; Hao Tang; Hong Du; Na Yao; Shuang-Shuang Liu; Lin-Na Liu; Zhe Zhang; Zhao-Wei Gao; Gang Nan; Qing-Yi Wang; Jian-Qi Lian; Zhi-Nan Chen; Ping Zhu
Title: Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial Document date: 2020_3_24
ID: 6g34qwer_3
Snippet: Findings 17 patients were enrolled and assigned to meplazumab group between Feb 3, 2020 and Feb 10, 2020. 11 hospitalized patients served as concurrent control. Baseline characteristics were generally balanced across two groups. Compared to control group, meplazumab treatment significantly improved the discharged (p=0.006) and case severity (p=0.021) in critical and severe patients. The time to virus negative in meplazumab group was reduced than .....
Document: Findings 17 patients were enrolled and assigned to meplazumab group between Feb 3, 2020 and Feb 10, 2020. 11 hospitalized patients served as concurrent control. Baseline characteristics were generally balanced across two groups. Compared to control group, meplazumab treatment significantly improved the discharged (p=0.006) and case severity (p=0.021) in critical and severe patients. The time to virus negative in meplazumab group was reduced than that in control group (median 3, 95%CI [1.5-4.5] vs. 13, [6.5-19.5 ]; p=0.014, HR=0.37, 95%CI[0.155-0.833]). The percentages of patients recovered to the normal lymphocyte count and CRP concentration were also increased remarkably and rapidly in meplazumab group. No adverse effect was found in meplazumab-treated patients.
Search related documents:
Co phrase search for related documents- adverse effect and concurrent control: 1
- adverse effect and control group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- adverse effect and crp concentration: 1
- adverse effect and lymphocyte count: 1, 2, 3
- adverse effect and meplazumab group: 1
- adverse effect and meplazumab group negative virus time: 1
- adverse effect and meplazumab treatment: 1
- adverse effect and meplazumab treatment control group: 1
- adverse effect and normal lymphocyte count: 1
- baseline characteristic and lymphocyte count: 1, 2, 3
- case severity and concurrent control: 1, 2, 3, 4
- case severity and control group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- case severity and crp concentration: 1, 2
- case severity and lymphocyte count: 1, 2, 3, 4, 5
- case severity and meplazumab group: 1, 2, 3, 4, 5
- case severity and meplazumab group negative virus time: 1
- case severity and meplazumab treatment: 1, 2, 3
- case severity and meplazumab treatment control group: 1
- case severity and normal lymphocyte count: 1
Co phrase search for related documents, hyperlinks ordered by date